Cancer research
What human research has studied for large trials on cancer risk; no supplement is proven to treat cancer, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where cancer research sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| European mistletoe | B | Quality of life during chemotherapy. The 2008 Cochrane review of 21 RCTs found some evidence of better quality-of-life measures during chemotherapy for breast cancer, from 2 higher-quality trials; the authors said these results need replication. sources |
| Shiitake | B | Survival in advanced gastric cancer (lentinan with chemotherapy). Individual-patient meta-analysis of 5 randomized trials (650 patients, unresectable or recurrent gastric cancer): adding lentinan to chemotherapy was linked to longer overall survival (HR 0.80, 95% CI 0.68–0.95). sources |
| Turkey tail | B | Survival after surgery for gastric cancer (PSK with chemotherapy). 2007 meta-analysis of 8 RCTs (8,009 patients): adding PSK to chemotherapy after curative surgery was linked to longer overall survival (HR 0.88, 95% CI 0.79–0.98). sources |
| Vitamin D | B | Cancer mortality. Three meta-analyses of clinical trials found supplementation reduced total cancer mortality by 12% to 13%; the most recent (10 trials) found the benefit greatest with daily dosing. sources |
| Boron | C | Cancer. Observational studies associate higher boron intake with lower risk of some cancers; ODS states no clinical trials have evaluated boron for cancer. sources |
| Boswellia | C | Brain swelling in people with malignant glioma. In a small study, oral boswellia may have reduced brain edema (swelling) but not the tumor; larger studies are needed. sources |
| Coenzyme Q10 | C | Cancer. NCCIH states CoQ10 has not been shown to be of value in cancer treatment, though it may reduce heart damage from one type of chemotherapy drug. sources |
| European mistletoe | C | Survival in people with cancer (extracts alone or added to chemotherapy or radiotherapy). A 2008 Cochrane review of 21 RCTs (3,484 patients) found the evidence on survival weak: 6 of 13 survival trials showed some benefit, but none was of high methodological quality. sources |
| Fucoidan | C | Quality of life during rectal cancer chemoradiotherapy. RCT in 87 patients: low-molecular-weight fucoidan improved physical well-being and reduced rash, itching and fatigue, but the overall colorectal quality-of-life score did not differ significantly. sources |
| Fucoidan | C | Tumor control with chemoembolization in liver cancer. RCT in 82 patients with unresectable hepatocellular carcinoma: low-molecular-weight fucoidan with TACE for 6 months raised disease control (95.24% vs 80.00%); objective response did not differ significantly. sources |
| Garlic | C | Stomach and colorectal cancer risk. NCCIH states consuming garlic does not seem to lower stomach cancer risk; its influence on colorectal cancer risk is uncertain. sources |
| Green tea | C | Cancer risk. Many studies, summarized in a Cochrane systematic review, have examined green tea and cancer risk; results are inconsistent. sources |
| Lycopene | C | PSA levels in men with non-metastatic prostate cancer. A 2021 meta-analysis of six RCTs found no significant overall effect of lycopene supplementation on PSA (WMD −0.60 µg/L); a reduction appeared only in studies of men with baseline PSA of 6.5 µg/L or higher. sources |
| Lycopene | C | Prostate cancer incidence. A Cochrane review found three RCTs (154 participants), two at high risk of bias, and concluded the evidence was insufficient to support or refute lycopene; only one trial reported prostate cancer incidence. sources |
| Maitake | C | Side effects of chemoradiotherapy in head and neck cancer. A randomized placebo-controlled trial in 141 patients reported that maitake D-fraction capsules taken during chemoradiotherapy reduced severe treatment-related adverse events and improved quality-of-life scores in advanced laryngeal and pharyngeal cancers. sources |
| Multivitamin/mineral supplements | C | Cancer incidence. PHS II found an 8% lower total cancer risk in men after a median 11.2 years; COSMOS (8,776 men and 12,666 women, median 3.6 years) found no reduction in total invasive cancers. sources |
| Pau d'arco | C | Isolated lapachol in chronic myelocytic leukemia. MSK reports that lapachol, a compound in pau d'arco, did not show clinical improvement in patients with chronic myelocytic leukemia. sources |
| Pomegranate | C | PSA rise in men with prostate cancer. Data conflict on whether pomegranate juice slows PSA rise in men with high PSA; in advanced prostate cancer, adjunctive juice did not reduce PSA versus placebo. sources |
| Propolis | C | Colorectal adenoma (cancer risk) biomarker trial. MSK reports that supplemental propolis was not useful in a pilot placebo-controlled trial in people with frequent colorectal adenomas, and had negative effects on muscle tissues including myocardial cells. sources |
| Reishi | C | Tumor response, immune measures and quality of life in people with cancer. Cochrane 2016: 5 RCTs of generally poor quality. Reishi added to chemo- or radiotherapy was associated with more tumor responses (RR 1.50, 95% CI 0.90 to 2.51, though the review reports P = 0.02) and small immune-marker changes; no trial measured long-term survival. sources |
| Reishi | C | Colorectal adenomas (precancerous polyps). Japanese study: 123 people took a mycelial culture extract (MAK) 1.5 g/day for 12 months; adenoma number and size decreased versus 102 untreated controls selected from the same department. sources |
| Riboflavin (vitamin B2) | C | Cancer risk. Cohort studies are mixed: some found inverse associations (lung cancer in current smokers; colorectal cancer in postmenopausal women), others none. ODS states clinical trials are needed. sources |
| Shiitake | C | Shiitake extracts added to standard cancer treatment. 2026 meta-analysis of 22 trials (1,723 patients): in 13 RCTs, tumor response was better (OR 1.45) but overall survival (HR 0.66, 95% CI 0.34–1.28) and quality of life did not differ. sources |
| Shiitake | C | PSA levels in prostate cancer. Open-label study of 62 men with prostate cancer and rising PSA: an oral shiitake mycelium extract for 6 months produced no PSA responses, and 23 of 61 progressed; authors judged it ineffective alone. sources |
| Soy isoflavones | C | Breast cancer risk. NCCIH: observational studies link higher soy intake in Asian and Asian-American women to lower breast cancer risk, but soy products in supplement form have not been shown to reduce breast cancer risk. sources |
| Sulforaphane | C | Cancer trials (prostate, breast, pancreatic, melanoma). A 2023 systematic review of 8 RCTs found changes in some genes and tissue biomarkers; PSA results in prostate cancer were inconsistent, and a survival difference in pancreatic cancer was not statistically significant. sources |
| Turkey tail | C | Side effects of treatment and survival in colorectal cancer. Cochrane 2022: 7 RCTs (1,569 participants), 6 in Japan. Low-certainty evidence of a small 5-year survival benefit (RR 1.08); very low certainty on side effects. Chemotherapy regimens do not reflect current practice. sources |
| Turkey tail | C | Lung cancer (PSK with standard treatment). A systematic review found 6 RCTs using PSK 3 g/day with chemotherapy; each reported benefit on at least one endpoint (immune measures, weight, performance status, symptoms or survival). sources |
| Turkey tail | C | Immune measures in breast cancer. Studies in breast cancer have measured changes in blood immune cells, not clinical outcomes such as survival, symptoms or quality of life. sources |
| Chaga | D | Cancer cells and tumors in the laboratory. Extracts and constituents such as inotodiol inhibited colon, lung, liver and cervical cancer cells in vitro and melanoma in mice; no human studies have tested this. sources |
| Calcium | X | Overall cancer risk. A meta-analysis of 10 RCTs (10,496 people, at least 500 mg/day, mean 3.9 years) found no change in total cancer risk; a 4-year RCT (2,303 women, 1,500 mg plus vitamin D) also found none. sources |
| European mistletoe | X | Survival and quality of life in advanced pancreatic cancer (MISTRAL trial). In a double-blind RCT in advanced pancreatic cancer (143 extract, 147 placebo, added to standard care), extract injected subcutaneously three times weekly for nine months did not improve overall survival (median 7.8 vs 8.3 months) or global quality of life. sources |
| Folate (folic acid) | X | Cancer. Trials do not show reduced cancer risk; a Norwegian trial (800 mcg with B12) found 21% higher incidence. A 2015 NTP panel concluded folic acid does not reduce cancer risk in people with adequate status. sources |
| N-acetylcysteine (NAC) | X | Second head and neck or lung tumors. MSK reports that a large trial found NAC did not inhibit formation of secondary head and neck or lung tumors. sources |
| Selenium | X | Cancer incidence and mortality. SELECT (over 35,000 men, 200 mcg/day selenomethionine) found no reduction in prostate cancer; a 2018 Cochrane review (10 trials, 27,232 people) found little to no effect on cancer incidence or mortality. sources |
| Vitamin A | X | Lung cancer in smokers (beta-carotene, with or without retinyl palmitate). In CARET (18,314 current and former smokers, including some asbestos-exposed men) lung cancer risk rose 28%; in ATBC (29,133 male smokers, 20 mg/day beta-carotene) it rose 18%. Overall mortality was also higher. sources |
| Vitamin B12 | X | Cancer. A meta-analysis of 18 RCTs (74,498 individuals; 20–2,000 mcg/day for 2–7.3 years) found little or no effect on cancer incidence. sources |
| Vitamin B6 | X | Cancer. Two Norwegian trials found no association between B6 supplementation and cancer incidence, cancer mortality or all-cause mortality; observational data link higher intake with 20% lower colorectal cancer risk. sources |
| Vitamin C | X | Cancer. Physicians' Health Study II (500 mg/day, mean 8 years) and the Women's Antioxidant Cardiovascular Study (500 mg/day, mean 9.4 years) found no effect on total cancer; most randomized trials show no effect on cancer risk. sources |
| Vitamin D | X | Cancer incidence. VITAL (25,871 adults; 2,000 IU/day D3; median 5.3 years) found no significant difference in breast, prostate or colorectal cancer; ODS states studies do not show supplementation reduces cancer incidence. sources |
| Vitamin E | X | Prostate and other cancers. SELECT (35,533 men, 400 IU/day synthetic, about 5.5 years) found no reduction in prostate cancer and, after 1.5 more years, 17% higher risk; HOPE-TOO and the Women's Health Study found no effect on cancer. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.